<?xml version="1.0" encoding="UTF-8"?>
<p>Our candidate vaccine did not induce enhancing antibodies against DENV-2. However, our data solely indicate that the ZIKV-induced antibodies did not enhance the NGC strain of DENV-2. It has been suggested that ADE may be serotype- and genotype-dependent [
 <xref rid="B54-vaccines-07-00072" ref-type="bibr">54</xref>,
 <xref rid="B55-vaccines-07-00072" ref-type="bibr">55</xref>,
 <xref rid="B56-vaccines-07-00072" ref-type="bibr">56</xref>], so we cannot exclude that infection of cells with other serotypes or genotypes could be enhanced by the ZIKV antibodies. Therefore, studies investigating enhancement activity of 
 <italic>flavivirus</italic> cross-reactive antibodies must include a panel of DENV-serotypes and genotypes. Taken together, our data show that CuMVttVLP-EDIII induces strong antibody response and that the use of adjuvant can skew the immune response in a Th1 direction.
</p>
